Background
Genetic analysis of cystic fibrosis transmembrane conductance regulator (CFTR) gene is fundamental for diagnosis, prognosis and personalized therapy of cystic fibrosis (CF). Despite CF is a monogenic disease, its genetics is not easy. Consequently, the genetic analysis of CFTR gene should take under account a lot of different situations that should be specifically handled.
Materials and methods
According to current definitions, the revision underway can be defined as a Consensus document. A group of 23 experts of SIFC composes the "working group for the revision of Consensus document about genetic analysis in CF". A list of the subjects to be treated was made by the working group. A first elaboration of each subject was done by small subgroups. The overall document was revised several times by the working group, harmonized and approved as a first draft. This draft is in submission for a first evaluation and revision to the board of SIFC and of the other scientific societies involved in the management of CF. After this revision, a further elaboration by the working group will be done, aimed to the inclusion of suggestions and to the production of a second draft to be finally approved by SIFC and other scientific societies. Results Three basic items of the Consensus document were identified: main text, risk tables and flowcharts. The first draft of the main text is ready. Risk tables and flowcharts will be added in the next step. The main text is composed of 6 preliminary sections: list of components of the working group; premise; abbreviations; definitions; abstract; introduction. Then, there are 7 general chapters: general description of the disease; genetic counselling; general strategies of mutational search (with appropriateness); mutational search in CF; mutational search in CFTR-related disorders; preimplantation mutational search; characterization of novel, rare and uncharacterized sequence variations. The next chapter describes specific strategies of mutational search and is divided into 13 sections each concerning mutational search applied to specific practical cases. The document finishes with the following 4 chapters: quality assurance; report; databases, website and software; references.
Conclusions
The need of documents assuring a homogenous behavior of geneticists and molecular biologists performing the CFTR genetic test is particularly felt. The last update of this type of document in Italy was done in 2005. The revised Consensus document will be an updated valuable practical guide, based on solid scientific evidences, for CF healthcare professionals. The main aim of clinical microbiology is the identification of bacterial, viral, fungal, and parasitic agents that cause human diseases, to enable an optimized clinical management of patients as well as to prevent infectious diseases transmission. In the last years the clinical microbiology has changed rapidly: in addition to culture-based methods that remain irreplaceable in routine clinical microbiology, news tools have been implemented, providing improved sampling and culture strategies and culture-independent methods. The inclusion of matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry (MALDI-TOF MS) as diagnostic tool has improved the accuracy of pathogen identification and shortened the time to achieve the final results. The technological advances in non-cultured methods have unveiled a much larger human-associated microbiota than was expected. The airway microbiome has been found to be much more diverse than previously thought based on bacterial culture, and relationship between that diversity and pulmonary function has been identified. This review summarizes the state of the art of culture methods and molecular techniques in clinical microbiology laboratory. The most advanced level of newly developed techniques includes disease-based sampling kits, new culture approaches, direct pathogen detection, point-of-care (POC) testing and clinical isolate identification with MALDI-TOF MS. Despite the advent of cutting edge molecular-based (real time PCR, 16S rRNA sequencing, next-generation sequencing) and protein-based microbial identification tools, there is an enormous need to continue culture-based testing to assess susceptibility to all antimicrobials and to identify pathogens with mutations that may escape detection by new technologies. Rapid detection and identification of infectious agents in clinical specimens are mandatory to implement appropriate therapeutic measures. For this purpose it is clear that combining culture based methods and molecular techniques can contribute to clinical management of airway infection, highlighting the importance of making these two methods complementary.
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Growth in Italy in the first two years of life. Data from the Italian Cystic Fibrosis Registry Rita Padoan 1 , Barbara Giordani 2 , Annalisa Amato 2 , Fabio Majo Background Cystic fibrosis (CF) is a progressive genetic disease that affects multiple organ systems. Therapy is directed to maintain and optimize nutritional status and pulmonary function, as these are prognostic factors for maintaining good lung function during the pediatric-adolescent age and key factors in survival. For infants and young children, the aim is to achieve the 50th percentile of weight and length for a healthy same-age population up to age 2 years.CF diagnosis by means of neonatal screening, ever more precocious, offers the great opportunity to correct pancreatic insufficiency since its inception, thus enabling the correct therapy to achieve a good nutritional status for all children. However, as shown by studies in different CF population, this target is not achieved for all subjects. The purpose of this report is to present the growth data of children aged up to 24 months enrolled in the Italian Cystic Fibrosis Registry, in the years 2011-2014.
Materials and methods
Registry data of the period 2011-2014 were evaluated. Indicators used to assess growth and nutritional status were weight/length (W/L), and length per age. Data were analyzed by age (groups: 0-6 months, 7-12, 13-18, 19-24) and for each year of data collection. The indicators were standardized with the calculation of the z-score.
Results
The Table 1 presents the data (median z-score for length per age and percentage of infants with W/L z-score >50°centile) for the years 2011-2014. With regard to weight per length, the lowest median zscores are found each year in the 0-6m age group. Recovery takes place within the first 12 months of life in most patients: for all years of study, the median z-score has passed from a negative value in 0-6m group, to values around zero in the subsequent age groups, with progressive increase of children with parameters above 50°centile and progressive reduction of children below 10°centile.
Conclusions
Children with CF are born smaller than the average [1] and can already present at the time of diagnosis pancreatic insufficiency that has already impaired their growth. The six month figure therefore reflects the short period of diagnosis and the beginning of appropriate therapy. Over the period considered, at the age of 19-24 months, more than half of the infants have a W/L z-score above the 50°c entile.
The increasing interest in molecular biology applied to diagnostics is the result of the deep advances in scientific knowledge in genetics made possible by the introduction and the continuous development of applied technologies. The number of laboratories using molecular biology techniques is growing rapidly and the inevitable consequence of this "demographic explosion" is the need for standardization as well as a definition of the organization of laboratories. Guidelines recommend the participation of laboratories performing genetic testing in internal Quality Control processes, as well as in Quality Control Programs (CEQs). The importance of laboratory participation in CEQ programs is recognized internationally. Currently, quality control programs for the molecular analysis of the CFTR gene are available both at the Italian and the European level. In Italy the document of the State Region Conference of July 15, 2004 established that the Institute of National Public Health (Istituto Superiore di Sanità ISS) as the competent office to evaluate the technical and professional quality of the operators through external quality controls. Participation is open to both private and public laboratories. In 2016, ISS examined 62 laboratories, each having received four DNA aliquots together with clinical and technical information. The laboratories sent back through a computerized system raw data and reports, written according to their standard format. Raw data and references were then evaluated by experts and a performance rating assigned: sufficient or insufficient.
The evaluation was done following the general evaluation criteria on the CNMR website at http://www.iss.it/tege/index.php. An analogous scheme is proposed at European level by the European Cystic Fibrosis Thematic Network, which is a project approved under the 5th framework program of the European Union. This project is coordinated by the Human Genetic Center of the University of Leuven. Currently, CF Network collaborates with EuroGentest's European Molecular Genetics Quality (EMQN) in order to improve the harmonization of external quality evaluation systems in Europe. At the moment the CF network, in order to improve harmonization of External Quality Assessment (EQA) schemes within Europe, works Background Homologous replacement can be used to modify specific gene sequences of chromosomal DNA in a process called "Small Fragment Homologous Replacement" (SFHR). A wild-type small DNA fragment (SDF) is used to correct the mutated genomic target. Cellular responses and molecular mechanisms involved in SFHR are only partially understood. Different DNA repair pathways and cell cycle checkpoints, as well as specific genes (as for example Trex1), appear to mediate the cellular response. This approach can be used as therapeutic CFTR correction aimed at restoring the wild-type CFTR sequence. Recent studies have shown the possibility to expand patient-derived epithelial cells from different human tissues, through the "Culture Reprogramming Condition" (CRC) methodology. The possibility to obtain with high efficiency large amounts of primary epithelial cells with stem-cell properties from CF patients with different mutations would represent a pivotal advancement for CF gene targeting.
Materials and methods
To optimize the efficiency of SFHR, we developed a reporter based assay system where the replacement frequency is quantified by cytofluorimetric analysis following restoration of a stably integrated mutated eGFP gene in the genome of SV-40 immortalized mouse embryonic fibroblasts (MEF). Electroporation was performed using both Amaxa Nucleofection System (Lonza) and Attractene (Qiagen) reagent. For the quantitative expression analysis of involved genes, arrayed real-time PCR was performed. CRC technology consists of coculture of primary epithelial cells with irradiated mouse fibroblasts as feeder layer, in the presence of the Rock inhibitor Y-27632. A preliminary setup and characterization of CF-CRC cells, obtained, after consent, from nasal brushing of CF patients, were performed. Results Amaxa Nucleofection System showed higher transfection efficiency than the Attactene reagent, respectively 76% and 25%. Both transfection systems presented high cellular toxicity, enhanced by the SDF. Best correction conditions in MEF consisted in G2/M phase cell cycle synchronization associated with hypomethylating treatment and low Trex1 gene expression. These conditions correlate with 0.071% of eGFP correction. CF-CRC cells resulted to express typical stem-like cell markers and retained the ability of re-differentiate to respiratory epithelium. Their CFTR mRNA resulted physiologically expressed and its sequence, as well as that of CFTR genomic DNA, resulted unmodified in respect to that of corresponding patient. Conclusions SFHR manipulations and molecular targets useful for increasing the replacement efficiency have been evidenced. Modulation of overall pathways and specific genes (for example Trex1) are suitable for a better comprehension of SFHR mechanism. The CRC technology applied to CF patient-derived cells may expand the supply of functional CF respiratory stem-like and differentiated cells for testing personalized therapeutic strategies, including drug testing and cellular therapy approaches. Background Cystic fibrosis (CF) is the most common genetically determined, lifelimiting disorder in populations of European. The genetic origin of CF is the mutations in the CF transmembrane conductance regulator (CFTR). CFTR mutations may be classified into 6 different categories based on the mechanisms that are affected. Class I results from mutations leading to absent CFTR production. Class II, including Phe508-del, are caused by defective CFTR processing. Class III mutations result in expression of CFTR, the channel gating is defective and results in impaired chloride transport function. Conductance defects are seen in class IV mutation. Class IV result in a milder phenotype. Finally, class VI mutations are characterized by a functional but unstable CFTR. Ivacaftor is a potentiator that augmented chloride transport and increased airway surface liquid height and cilia beat frequency in airway epithelial cells expressing a CFTR gating mutation (III Class).
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Materials and methods
Between September 2015 and September 2017 at the Regional Reference Center for the CF of Palermo, a total of 7 patients (female:4, male:3) aged 8-42 years (mean 25,6) with CF, carriers of a CFTR channel gating mutation, were enrolled and assigned to receive Ivacaftor (150 mg x2/die). We evaluated auxometry (weight, hight and BMI), respiratory function by spirometry (%FEV 1 %FVC), liver, pancreatic and renal function, sweat test, respiratory infections and CF Questionnaire-Revised (CFQ-R). Nobody used to take CYP3A-inhibitors.
Results
We observed the improvement of respiratory function in term of FEV1 and FVC after only 3 months of observation. In fact the percent of FEV1 was +0.9% at T 3 , +3,6% after six months (T 6 ) and +3,2% after two years (T 24 ). FVC got better: + 3,4%, +3,18% and + 3,4% respectively at T 3 , T 12 , T 24 . The nutritional state was evaluated by the mean of Body Mass Index that increased of 2,02 points after 24 months of observation: from 21,28 Kg/m 2 at T 0 to 23,3 at T 24 ( Table 2 ). The health perception was investigated by the CFQ-R respiratory symptom scale: +14 points percent from T 0 to T 24 . During this time we detected 10 pulmonary exacerbations. We didn't record any side effects, particularly monitoring liver function.
Conclusions
We are living a new era of precision medicine in CF. Kalydeco is an example of innovative therapeutic strategy for carriers of a CFTR channel gating mutation. We demonstrated the improvement of respiratory function in 24 months of clinical observation without side effects.
Further studies are needed to demonstrate the efficacy of this new drug in the clinical practice. Consent for publication: The patients gave the consent to publish clinical data. 
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Background
Prior studies with CFTR modulators in pts heterozygous for F508del and a minimal function (MF) CFTR mutation (F508del/MF) have failed. One strategy to enhance clinical efficacy is to add a second corrector to established corrector/potentiator regimens. Safety and efficacy of 3 such next-generation (NG) correctors (VX-440, VX-152, VX-659) in triplecombination therapy (TC) with tezacaftor (TEZ) and ivacaftor (IVA) were evaluated in CF pts with F508del/MF or F508del/F508del genotypes.
Materials and Methods
Randomized, double-blind, placebo (PBO)-or active-controlled studies of VX-440 and VX-152 (Ph2), and VX-659 (Ph1) in TC were conducted in F508del/MF or F508del/F508del (VX-152 and VX-440 only; after 4 wks of TEZ/IVA pretreatment) CF pts. Primary objectives were safety and tolerability; efficacy was assessed by absolute change in ppFEV 1 from baseline (BL) and pharmacodynamic effect by change in sweat chloride from BL. Results BL characteristics were balanced. NG TC regimens were well tolerated; most AEs were mild or moderate. AEs leading to discontinuation included increased ALT/AST (VX-440 TC, n=1), pneumonia (VX-152 TC, n=1), and respiration abnormal/sputum increased (PBO, n=1). After 2 to 4 wks, improvement in ppFEV 1 of 9.6 to 12.0 percentage points was seen with all 3 NG TC regimens in F508del/MF pts, and 7.3 to 9.5 percentage points with VX-440 or VX-152 TC on top of TEZ/IVA in F508del/F508del pts (vs TEZ/IVA BL). Significant reductions in sweat chloride were also seen (Table 3) . Conclusions This is the first demonstration of substantial improvements with NG TC regimens in F508del/MF CF pts, where previous CFTR modulators have failed, and in F508del/F508del CF pts. Ongoing phase 2 studies will guide development of future TC regimens. Background Stem cell-based therapy offers the opportunity to treating CF patients independently of mutation class. The amniotic membrane has been shown to be an ethical source for stem cells, since it is discarded after parturition. Human mesenchymal stem cells derived from the amniotic membrane (hAMSCs) display interesting properties for the purposes of treating CF lung disease, having the capacity to differentiate into epithelial cells, showing anti-bacterial activity and modulating the inflammatory process. We previously found that hAMSCs in co-culture with CF immortalized airway epithelial cells (CFBE41o-line, CFBE, homozygous for the F508del mutation) on Transwell filters acquired an epithelial phenotype and lead to the rescue of a mature and functional CFTR protein (Paracchini et al., J. J Biomed Biotechnol. 2012;2012:575471; Carbone et al., J Cell Mol Med. 2014;18:1631-43). The studies also highlighted that the rescue of CFTR was absent when separate co-cultures were obtained suggesting that cell-to-cell contacts are necessary for obtaining the F508del CFTRdependent rescue. 
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Materials and Methods
In order to explore the role of gap junctions (GJs) in this rescue, cocultures (hAMSC:CFBE, 1:5 ratio) were studied for the formation of GJs, before and after silencing them with siRNA directed against connexin 43 (Cx43), a major component of GJs. Under these experimental conditions, GJ-mediated intercellular communication was studied by the transfer of lucifer yellow, CFTR expression by confocal microscopy and Western blotting, while its activity by spectrofluorimetric measure of chloride efflux. Results Cx43 specific siRNA mediated down-regulation of Cx43 mRNA and protein, whereas a scrambled siRNA had no effect. Co-cultures could form functional GJs that were inhibited when the Cx43 protein expression was down-regulated. Transfection of co-cultures with siRNA against Cx43 resulted in the absence of CFTR expression on the apical membrane and reduction in the mature form of CFTR (band C), paralleled by the significant decrease in CFTR-dependent chloride channel activity.
Conclusions
These results indicate that GJs are involved in the correction of CFTR chloride channel activity upon the acquisition of an epithelial phenotype by hAMSCs in co-culture with CF cells. These results may indicate that undifferentiated hAMSCs may be administered to the CF lung where they would rescue CFTR expression and function by forming GJs. Further exploration of the usefulness of hAMSCs in the rescuing of CFTR-dependent basic defects involved in the pathogenesis of CF lung disease should be studied in primary airway epithelial cells obtained from CF patients and in "in vivo" models. Background Impaired glucose tolerance and cystic fibrosis related diabetes (CFRD) negatively affect respiratory function measured by FEV1. Insulin secretory defects are risk factors for CFRD and may be also related to early lung function abnormalities that cannot be detected by spirometry. Our aim was to assess the correlation between OGTT-derived indices and the Lung Clearance Index (LCI), a more sensitive marker of early lung abnormalities than FEV1.
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Materials and methods
We performed a Multiple-Breath Washout Test in 61 CF patients with a mean age of 18 years (range: 10-30) who underwent an OGTT as part of their annual screening for CFRD. From OGTT, we retrieved data on 2h plasma glucose (as a marker of glucose tolerance) and 30 min plasma insulin (as a marker of early insulin response). We compared LCI values across strata of glucose tolerance and quartiles of 30 min plasma insulin after OGTT. Moreover, we fitted multiple linear regression models to take into account the potential confounding effect of sex and age. Results According to the OGTT, 7 patients (11.5%) had diabetes without fasting hyperglycemia and 11 patients (18%) showed impaired glucose tolerance. Patients in the lower quartiles of 30 min plasma insulin after OGTT had increased LCI values as compared to the higher quartiles (median across quartiles: Q1: 14.5, Q2: 15.8, Q3: 12.7, Q4: 11.0, P= 0.029), while the LCI was not significant different (P= 0.30) among patients with diabetes (14.6, IQR: 12.1; 19.0), glucose intolerance (14.1, IQR: 13.0; 17.1) and patients with normal glucose tolerance (median: 13.4, IQR: 9.9; 16.4). In multiple linear regression models adjusted for sex and age, 2h plasma glucose (β= 0.03, P= 0.016) and 30 min plasma insulin (β= -0.04, P=0.01) were significant predictors of LCI.
Conclusions
In CF patients, hyperglycemia and reduced early insulin response are independently associated with early lung function abnormalities, as detected by LCI. Our results could help to clarify the role of insulin secretory defects in the deterioration of respiratory function in CF. Background Scientific literature about pregnancies in women with a diagnosis of cystic fibrosis (CF) is still scattered. Family planning in this group of women is becoming commoner with health improvement and survival increase. The objective of the study is to assess the maternal health status of patients with cystic fibrosis through the analysis of maternal outcomes.
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Materials and methods
We conducted a longitudinal analysis of functional outcomes in pregnant women over the period 2010-2015, using records from the Italian Cystic Fibrosis Registry (ICFR). Cases were matched by age and genotype with never pregnant control subjects (1:2). Characteristics at baseline were outlined in both comparison groups. Changes in lung function and nutritional outcome (BMI) were also assessed. Results A total of 84 pregnancies were identified in 81 women. Median maternal age was 31 years. Pancreatic insufficiency was reported in 50% of pregnant women. 55% presented a BMI <22, 44% had a moderate-severe respiratory function (FEV 1 % predicted <70%). Chronic P.aeruginosa was present in about half of cases. Evidence of difference in median age at CF diagnosis was found between pregnant and never pregnant women (P<0.05). A decrease in lung function was found statistically significant in pregnant women over the period 6-12 months before pregnancy and 12 months after delivery (P<0.5). No significant differences were found over the same study period between pregnant and the control group in nutritional status and lung function. Only one patient died 14 months after delivery. Conclusions This study showed a decline in lung function over the ante-post pregnancy period in patients with cystic fibrosis. However, further investigations are needed to improve knowledge about the long period impact of pregnancy on the cystic fibrosis disease. We would like to thank Italian CF Centers, which provide data to ICFR 
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Background
Atelectasis is a common complication in cystic fibrosis (CF) patients. Several patients do not respond to standardized therapies. As persistence of atelectasis is associated with poor outcome, bronchoscopy can represent an alternative tool for the treatment of this complication. Few data are available for its routine use. Our objective was to evaluate the efficacy of bronchoscopy as a therapeutic tool in CF pediatric patients with atelectasis/subatelectasis not responding to conventional therapies.
Materials and methods
Since 2013 10 CF patients with atelecatsis underwent one or more bronchoscopies. For each patient, microbiological and radiological data, respiratory function (FEV1% and MMEF%) were collected. Flexible Olympus Bronchoscopy was used. Broncho-alveolar-lavage was performed and mucolytics and antibiotics were instilled. In few occasions surfactant was employed. Following the procedure, patients underwent PEP-Mask respiratory physiotherapy/non-invasive ventilation in C-PAP mode; after 48-72h RX chest was performed. Subsequently, patients were regularly followed.
Results
Ten patients (4 males) were enrolled (mean age 9.6±4.7 years, 6 months-16 years); 9/10 had pancreatic insufficiency. Indication for 1st bronchoscopy was always the radiological finding of atelectasis/subatelectasis not responsive to conventional therapy. In 7/10, radiological examinations showed a single atelectasis (2/7 due to ABPA); in 3/10 multiple atelectasis. 7/10 and 3/10 underwent a single and repeated bronchoscopy (through a mean period of 6 months) respectively. 18 procedures were performed: dornase-alpha was always used and in 17/18 patients it was associated with 7% hypertonic solution and hyaluronic acid. In 15/18 procedures colistin (14/18) or tobramicin (1/18) was instilled in case of Pseudomonas aeruginosa infection, while in 2/18 vancomycin in presence of Staphylococcus aureus. In 2/18 cases, surfactant was used for the largest extension of the atelectasis area. In patients undergoing a single procedure, complete resolution of atelectasis was observed in 6/7, while in 1/7 resolution was partial. In 3/10 patients undergoing repeated bronchoscopy, complete resolution of atelectasis was observed in 1/3 after 3 procedures, in 2/3 X-ray showed a partial improvement. The mean values of FEV1% and MMEF% pre and post-bronchoscopy increased significantly (M±DS 74.69±12.44 vs 84.00±16.58; p<0.005; 40.62 ± 14.68 vs 55.23±23.01, p<0.005 respectively). Conclusions Bronchoscopy can play an important role in resolution of atelectasis. Our results show that the procedure is well tolerated and can lead to radiological resolution of atelectasis even after a single procedure. Clinical benefits were evident in terms of statistically significant improvement of spirometry parameters. A national longitudinal observational study could be useful to draw up a standardized protocol. Consent for publication: Written informed consent was obtained from the patient's parents. 
Background
Despite new medical therapies that have delayed the progression of lung disease with the consequent improvement of life expectancy, lung transplantation is currently the only treatment for end-stage respiratory insufficiency in patients with cystic fibrosis (CF). In this study we analyzed retrospectively our center's experience since start of the transplantation program in 1996 with focus on survival analysis.
Materials and Methods
We reviewed CF transplant database and patient charts. Survival rates were calculated and compared between four era from 1996 to 2016. Categorical data were presented as number and percentage and comparisons done using the chi-square (χ 2 ) test or Fisher's exact test. Numeric data were presented as mean ± standard deviation (SD), for normally distributed data and comparisons done using the two sample independent t-test, while non-normal numeric data were presented as median (range).
Results
In a 20-year period, 243 patients with CF were listed for lung transplantation; 125 patients (62 males, 63 females) underwent transplantation and 85 patients died while waiting for donor organs. The mean and median age at transplantation was 27 ± 8 SD and 26 (range 9-52) years, respectively. FEV1 was 27.7 ± 6.3 % predicted, 115 patients (92 %) were pancreatic insufficient and 43 patients (34 %) had diabetes CFrelated. Overall 1-year survival after lung transplantation for CF was 71.2 %, 5-year survival was 56.9 %, 10-years survival was 46.8 %, 15-year survival was 31.6 % and 20-years survival was 35%. Removing CF patients who died within the first three postoperative months, the mean and median survival after transplantation were 8 ± 5.6 SD years and 7.1 years (range 3 months -20 years), respectively. We found a trend for gender difference in survival rate (CF males 7 ± 6.2 SD years versus CF females 5.4 ± 5.6 SD years, p < 0.07). Conclusions Lung transplantation is a well-established life extending treatment for patients with CF. Survival after lung transplantation in our centre is good, although slightly lower than the international data. Further analysis is needed to identify the multifactorial mechanisms that might have contributed to reduce outcomes at our center. Background Allergic bronchopulmonary aspergillosis (ABPA) is a pulmonary disorder, which occurs in patients with chronic lung diseases such as Cystic Fibrosis (CF). ABPA results from hypersensitivity to Aspergillus antigens which determines airways inflammation, bronchiectasis and bronchospasm. Conventional therapy consists of the use of steroids combined with anti-mycotic drugs. In conventional treatment-resistant cases, it is accredited therapy with Omalizumab, a recombinant humanized murine monoclonal antibody that binds to free IgEs, impinging on the receptors present on mastocytes and basophils. This article describes our experience on the use of anti-IgE monoclonal antibody in three CF patients with ABPA. Case Reports I, A 17-year-old male CF patient was admitted to our hospital for respiratory distress, wheezing and persistent cough. His sputum cultures were chronically positive for S.aureus and recently positive for Aspergillus fumigatus (Af). He complained of persistent dry cough and his FEV1 has progressively reduced from 75% to 40% of predicted. Total IgE were 1324 UI/ml, specific IgE for Af levels were 23.9 kUA/l and IgG antibody to Af were positive, making possible the diagnosis of ABPA. Thus, we started treatment with Prednisone and Itraconazole. However, after several weeks his general conditions worsened. We decided to start treatment with Omalizumab according to standard protocols. Symptoms and FEV1 improved after the second administration. At week 8 of therapy, his FEV1 raised to 83% predicted. After three months IgG antibody to Af were negative and after one year total IgE were <363 UI/ml. II, 11-year-old male CF patient was admitted due to chronic respiratory failure.His airways were chronically colonized from for P.aeruginosa and in the previous two months from Af. Targeted antibiotic therapy was administered without clinical improvement. Total IgE 988 UI/ml, positive skin prick tests, RAST and airways cultures for Af, were directed towards a diagnosis of ABPA. Despite of steroids and antifungal therapy, he did not improve. Therapy with Omalizumab was started with improvement (FEV1 increased of 25%). III, 42-year-old male patient with late CF diagnosis and ABPA, total IgE 988 UI /ml, skin prick test, RAST and positive sputum cultures for Af. His general conditions were poor with persistent cough and impaired lung function. After conventional therapy, which did not lead to some improvement, Omalizumab was started also in this case with a FEV1 increase of 22%. Conclusion Our experience demonstrates that treatment with Omalizumab may definitely improve general conditions and lung function in CF patients with ABPA refractory to conventional therapy. Consent for publication: All patients gave the consent to publish clinical data. Declining pulmonary function is associated with the Resting Energy Expenditure (R.E.E.) increase from 10 to 20%. Chronic lung disease exacerbations lead to an increased R.E.E. value, which returns to basal levels some weeks after resolution of inflammation. Attempting to balance the energy gap justifies precocious and aggressive nutritional intervention, which begins in the early years and continues throughout life. However, an increase in caloric intake is not sufficient to neutralize protein-calorie need resulting from R.E.E. value growth. Non-energy intake results in reduced respiratory muscle function and decreased exercise tolerance, causing a chronic and irreversible deterioration in patient status, until death.
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Materials and methods
The aim of our study is to observe and analyze the evolution of Plasmatic AminoAcids in a sample of 34 CF patients, 17 men and 17 women, treated with appropriate low-carb, high-fat, high-calorie, high-glucose diet, tailored to anthropometric values, age and gender, as well as recommended by the latest guidelines, and to assess a possible correlation with the patient's clinical phenotype nutritional state. Results Aminoacidogram showed that: 16/34 patients (47%) had significantly reduced Plasmatic Amino Acid levels; when considering patients with severe malnutrition, 63% presented an altered Amino Acid profile, although 30% of those with good nutritional status also had lowered levels (Table 4) . These results suggest the presence of a metabolic disorder, which does not depend solely on nutritional status.
Conclusions
In conclusion, the amino acid profile seems to be influenced by different factors and somehow identifies a "metabolic disorder" that characterizes CF. Furthermore it does not appear to be outweighed only through highcalorie diet. Future studies and larger clinical samples will be needed. Consent for publication: The patients gave the consent to publish clinical data. and clinical manifestations (phenotype) of Cystic Fibrosis (CF) is still difficult to understand completely. CFTR gene produces a primary transcript of 6132 bases; a complex transcriptional regulation occurs on the entire locus of the gene, with a dynamic not yet completely clear. In order to study the possible mechanisms involved in the modulation of these processes, we have conceived a study that analyzes selected intragenic haplotypes, possibly modulating CFTR expression, in different populations of CF and CF-like patients.
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Materials and Methods
From a previous work, we selected eight markers (six SNPs and two polymorphic traits), that we analyzed through DNA sequencing of the CFTR gene in the following seven different populations: men with idiopatic seminal hyperviscosity (ISHV) and with congenital bilateral absence of vas deferens (CBAVD), patients with CFTR related disorders (CFTR-RD), CF patients with or without pancreatic sufficiency (CF-PS and CF-PI) as target populations; general population (GC) and normospermic men (NC) as controls. We obtained RNA samples from nasal brushing of selected patients, previously genotyped. RNA was analyzed by reverse transcriptase PCR assays to study a possible induction of anomalous splicing based on the single variations composing the haplotype. Results Data analysis highlighted statistically significant differences in frequencies of selected haplotypes (frequency >5% in at least one population) between populations with different clinical manifestations. Our study shows that some haplotypes are more frequent in target populations compared to controls; in particular, one haplotype marks 63% of FC-PI, 33% of FC-PS, 36% of CFTR-RD, 20% of CBAVD, 13% of ISHV, 3% of GC and 6% of NC alleles. No anomalous splicing was produced by the individual sequence variations. Studies concerning the modulation of the CFTR mRNA levels by the presence of selected haplotypes in populations under investigation are still running. Conclusions Our results confirm that the simultaneous presence in cis of multiple variations composing particular haplotypes is characteristic of some CF and CF-like populations in respect to controls. We hypothesize that the presence of a specific haplotype, rather than single variations, can affect the processing of the primary transcript of the CFTR, reducing its level. Moreover, haplotypes may be markers of mutated alleles that may be associated with different clinical manifestations. The use of haplotypes can be the basis of broad-spectrum screening programs, with a considerable saving of costs and reduction of investigation times. 
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Background
The US-FDA expanded approved use of Ivacaftor to 28 mutations determining a residual functioning (RF) CFTR protein. This decision let about 1,500 subjects with CF (about 5% of US patients) to treat with Ivacaftor. The European Registry 2014 report described the rates of a few RF variants (3849+10kbC→T in 0.82% of tested alleles, 2789 +5G→A in 0.95%, D1152H in 0.52%). Italian Registry reported about 10% of patients carrying one of these mutations in 2014. The high prevalence of these mutations and the particular Italian genetic background encourage to describe prevalence and phenotype of RF variants.
Materials and Methods
A query was made to the Italian Registry about the patients carrying the mutations: 2789+5G→A, 3849+10kbC→T, 3272-26A→G, 711 +3A→G, E56K, P67L, R74W, D110E, D110H, R117C, L206W, R347H, R352Q, A455E, D579G, E831X, S945L, S977F, F1052V, R1070W, F1074L, D1152H, D1270N, K1060T, E193K, A1067T, G1069R, R1070Q. Data (2015 database) were retrieved about diagnosis, nutrition, lung function, complications, microbiology. Results of RF patients were compared with those of F508del homozygous subjects.
Results
Main results are shown in Table 5 . 780 subjects were identified over a total of 5204 (15%); males were 392 (50.3%), mean age was 27.3 years. Diagnosis was made meanly at 13.7 years, with a mean sweat chloride of 75.8 mmol/l, by symptoms (55.8%), screening (26.8%), familiarity (11.3%) and male infertility (4.7%); meconium ileus was rare (0.8%). Nutrition is good with mean BMI z-score 0. 3 The poly-T tract, located at the junction of intron 8 (IVS-8) and exon 9, is well known. It influences transcription, and thereby reduces the amount of normal CFTR protein. The number of T residues present, 5, 7 or 9, affects the splicing efficiency of exon 9. If the T5 allele is present, a proportion of CFTR transcripts will lack exon 9, which produces a nonfunctional protein and variable CF symptoms. The TG repeats, 5' of the poly-T, also influence splicing of exon 9, and when present on the same allele as a 5T repeat, the longer the TG-repeats, the higher the proportion of CFTR transcripts that will lack exon 9. In this report we describe the finding of a new (TG)13T6 allele.
Materials and methods
In this study, we described a pregnant 36 years old woman, who has come to our attention for CF screening. The analysis has been performed by means of Next Generation Sequencing with Multiplicom MASTR™ Dx (Multiplex Amplification of Specific Targets for Resequencing) using MiSeq platform. Data analysis has been carried out by Sophia Data Driven Medicine (Sophia DDM), Sophia Genetics®. In addition, we performed a nasal brushing of the patient. RNA was extracted, reverse transcribed and amplified using standard methods. RT-PCR results were analyzed by a semiquantitative densitometric assay.
Results
The genomic analysis did not reveal any known pathogenic variant, but it showed an atypical poly-T/TG repeats genotype. The patient was characterized as c. 
Materials and methods
We evaluated the use of digital droplet PCR (ddPCR) with EVAGreen technology to quantify the amount of exon skipping due to splicing mutations. In particular, we used total RNA extracted from nasal cells brushed directly from subjects bearing different intron 9 polyT variants, including the 5T-12TG allele. The total RNA was retro-transcribed and amplified by ddPCR using a single primer pair to amplify both PCR products, 305 bp (correct splicing) and 122 bp (Exon 10 skipped).
Results
Using a single primer pair it was possible to determine different percentage of exon 10 skipping depending on the poly T tract size, as reported in literature. In particular, we obtained about 50% and 95% correct splicing from 5T/7T and 7T/7T subjects. Conclusions These data, even if preliminary, strongly suggest that it is possible to accurately quantify the percentage of correct residual splicing with a simple pair of primers, without the use of special probes. This methodology could be helpful especially in the analysis of composite heterozygous, in which splicing mutations are associated with other severe mutations and it is necessary to know the exact contribution of the splicing variant to the phenotype. 
Background
Mutations of CFTR gene, responsible of Cystic Fibrosis (CF), cause abnormal chloride transport in the airways, pancreas, intestine, and vas deferens, leading to progressive lung and pancreatic dysfunction, elevated sweat electrolyte levels and male infertility, respectively. Chronic pancreatitis (CP) is a complication of CF due to prematurely activated trypsin within the pancreas that plays a pivotal role in triggering the activation cascade of pancreatic digestive zymogens. We studied several genes belonging to different pancreatic pathways to evaluate if mutations in such genes may represent risk factors for CP also in CF patients.
Materials and methods
We enrolled: 48 patients affected by CF and pancreatitis, recruited through a multicentric study; 35 patients with CF without symptoms nor history of pancreatitis; 80 unrelated healthy controls. We designed a panel of 8 genes involved in the intrapancreatic activation of trypsin PRSS1, PRSS2, SPINK1, CTRC, CASR, CFTR, CTSB and KRT8 and 24 additional genes classified into four groups according to the activity of the encoded protein in the "Pancreatic Secretion Pathway" (PSP). Targeted resequencing was performed using a TruSeq Custom Amplicon Low Input technology (Illumina) with the MiSeq platform. All identified variants were analyzed with bioinformatic softwares evaluating the impact of the change in amino-acidic structure on protein functionality. The variants predicted as "damaging" by at least three of these softwares were validated by standard Sanger sequencing. The study obtained the approval of local ethical committees.
Results
We found 14 patients (29.16%) with mutations in genes involved in the intra-pancreatic activation of trypsin in the group of CF patients with CP, while mutations in such genes were found in 2/35 (5.7%) patients with CF without experience of CP and in 3/80 (3.8%) healthy subjects (chi square, p<0.001). Thus, we found mutations in 12 genes of 11 patients for the PSP in the cohort of patients with CF and CP. Finally, 14/48 patients (29.2%) showed one or more mutations in the genes involved in the intra-pancreatic activation of trypsin and 6 patients had also mutations in the genes involved in PSP. Of the remaining 34 patients, 5 presented mutations in at least one gene of the other pancreatic pathways of the panel.
Conclusions
This study suggests that the trans-heterozygous association between CFTR mutations and the genes involved in the pathway of pancreatic enzyme activation may be a risk factor and predispose to the development of pancreatitis in patients with CF. Background Transient nutritional disorders are common pathological conditions during childhood, especially when children progress throughout critical steps of their development. About 25% of children with a normal physical and mental development can indeed be affected by nutritional disorders. This percentage increases to 35% in children with developmental defects. Temporal continuity and the tendency to persist might determine the evolution of the difficulties in a real food disorder [1, 2] . Cystic fibrosis (CF) diagnosis can be a significant risk factor in the development of the primary relationship between caregivers and children, favouring anxiety and eating difficulties.
Materials and Methods
A qualitative research on nutritional issues and behavioural during meals was performed by the psychologist and the dietitian in CF pancreatic insufficient patients (aged 0 to 18 years). Clinical charts were reviewed and BMI centiles were recorded. In 0-2 years group weight/length centiles were collected. The study obtained the approval of local ethical committee.
Results
Seventy seven patients were selected for this study, their ages being: 0-2 years old: 8 patients; 3-5 years: 14 patients; 6-10 years old: 21 patients; 11-18 years old: 34 patients. 12% of parents reported inadequate behaviours during the main meals or described the necessity of using non canonical methods to feed their children (i.e., distraction, forced feeding); moreover 38% of parents described an anxious status correlated to their children' weight gain and referred to the moment of the weight check during follow up clinical visits.In Table 6 nutritional status and frequencies of eating disorders are showed in the different age groups.
Conclusions
The data analysed in our Centre showed that nutritional disorders are common pathological conditions among CF patients and they need to be considered carefully. Symptoms detected during the early childhood do not physiologically resolved and they have the tendency to persist during puberty and adolescence. Eating difficulty does not concern only patients with pathological BMI or at risk of malnutrition; we observed children with a normal BMI who are affected by mild or serious nutritional disorders and parents seriously worried about their child's growth, although the presence of a normal BMI. The high incidence of nutritional disorders among paediatric patients affected by cystic fibrosis highlights the importance of this topic. The medical staff with the help of the psychologist and the dietitian should carefully discuss possible strategies to avoid the onset of these conditions since the time of first communication with parents after CF diagnosis and during follow up. Background Nutrition is a main feature of the management of patients affected by Cystic Fibrosis (CF) and their nutritional status is directly related to pulmonary function and survival. Several studies suggest that a diet implemented with omega 3 fatty acid, such as Docosahexaenoic Acid (DHA), shows some anti-inflammatory effects, attenuates pulmonary and gastrointestinal symptoms, reduces the disease progression. Materials and methods DHA basic has been introduced as a nutritional supplement into the diet of 26 CF patients (12 males and 14 females) with an average age of 11,5 years affected by loss of weight and poor growth. All patients have been followed-up for 6 months monitoring weight, BMI, FEV1 and pulmonary exacerbations.
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Results
We found an average weight gain of 3,5 kg in 22 patients, whereas 4 patients did not show any weight modification. Spirometry has been performed on 12 patients, 6 of whom had an improved FEV1 with an average increase of 7%, 6 did not presented any change. Only 6 cases of pulmonary exacerbations, requiring hospitalization, have been observed. Conclusions Diet integration with DHA basic can be certainly considered as a part of the management of CF patients, because of the improvement of their nutritional and respiratory status. Our study strenghtens the evidences yet published about the anti-inflammatory effects of DHA, demonstrating both an improvement of auxological parameters and pulmonary symptoms, and a decrease of exacerbation episodes and subsequently of the use of antibiotics therapy. Consent for publication: The patients gave the consent to publish clinical data. Further study on larger populations will be crucial in order to better define Mc incidence and its ideal management in CF children. Consent for publication: The patients gave the consent to publish clinical data. Several resistance mechanisms make eradication of Bcc almost impossible and it is difficult to establish a correct therapeutic scheme since, to date, there is no method considered "Gold Standard" for in vitro determination of antibiotics sensitivity, nor MIC breakpoints specific for Bcc. Aims: conduct a retrospective survey to define prevalence of Bcc among patients attending the CF Center in Milan; assess frequency of the most isolated Genomovars and its variation throughout time; compare three different methods to determine the minimum inhibitory concentration (MIC) of several antibiotics.
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Moraxella catarrhalis in Cystic
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Materials and methods
We focused on 24 patients (mean age 29 years) chronically colonized with Bcc, out of the 838 attending our centre by the end of 2015. Biochemical tests and a subsequent recA gene sequencing were carried out to identify Genomovars of 151 strains of Bcc isolated from the low respiratory tract of these patients over the period between 2005 and 2015 (one strain per year per patient since first colonization). Antibiotic sensitivity tests were performed on 51 of these strains for six antibiotics with two manual methods, microdilution scalar redoubling (MSR) and Epsilometric E-Test, and an automated Microdilution Method (MicroScan WalkAway plus System, Beckman Coulter).
Results
Bcc prevalence value has increased steadily over the study period from 1.1% in 2005 to 2.9% in 2015, and 7 out of the 17 genomovars known today were recognized. The prevalence values of the different subspecies are: 45.8% for B.cenocepacia Genomovar III, 16.7% for B.stabilis Genomovar IV, 12.7% for B.multivorans Genomovar II, 8.34% for B.cepacia Genomovar I and B.vietnamensis Genomovar V, 4.16% for B.seminalis BCC7 and B.metallica BCC8. All patients maintained the same genomovar acquired at first infection. No significant correlation for any antibiotic was found among MIC values obtained through the three different chemosensitivity methods. Conclusions Bcc prevalence values observed over the years are in line with literature data. In Milan CF centre, infections are mainly sustained by B.cenocepacia Genomovar III, and all patients maintained the same Genomovar acquired at first infection, as the retrospective analysis shows. We assess the importance of a timely molecular typing of Bcc strains to guide the clinician dealing with CF colonized patients. The chemosensitivity results are consistent with EUCAST remarks in regard to poor reproducibility and therefore reliability of the tests. Background Chronic Pseudomonas aeruginosa (PA) lung infections are the major cause of morbidity and mortality in cystic fibrosis (CF) patients. During the initial phase of infection, patients can be treated with early eradication therapy to prevent or delay chronic PA lung infections. Following eradication, lung re-infection can occur with bacteria with the identical genotype. This may be due to re-colonization from the patient's paranasal sinuses. Although the CFTR defect equally affects respiratory cells in the upper airways (UAW) and lower airways (LAW), the microbiological assessment of UAW is not included in the standard of care. The aims of the study were to evaluate, using non-invasive methods, the microbiological status of UAW of CF patients not chronically infected with PA.
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Importance of upper airways in early P. Aeruginosa infection in CF
Materials and methods
During the period 2014-2017, 47 patients not chronically infected by PA, according to the Leeds' definition, were evaluated. We simultaneously sampled the LAW by expectorated sputum or deep throat swab and the UAW by nasal lavage, using the Mainz method. Genotyping of PA isolated from UAW and LAW were also performed by BOX-PCR in order to assess if the UAW may represent a re-infection source. Results A total of 64 nasal lavages and concomitant LAW specimens were analyzed from 47 patients (median age 13 years, range 2-48). During the study period 14 out of 64 (22%) nasal lavage and 32 (50%) LAW were found positive for PA. Positive samples were found simultaneously from upper and lower airways in 10 (15.6%) out 64 specimens and they carried identical PA genotypes in the two compartments. In 4 patients PA was cultured from the UAW after successful eradication therapy. PA isolates from UAW showed high susceptibility to the majority of tested antibiotics. No resistance to colistin, meropenem or ceftazidime was found. Only 2 PA isolate showed a mucoid phenotype.
Conclusions
The presence of PA isolates in the nasal lavage suggests that the UAW can play a role in the acquisition and/or persistence of these bacteria, even after eradication therapy, this may be due to the fact that the UAW is undertreated in CF. Since the PA strains isolated from the UAW had low antibiotic resistance, the efficacy of antibiotic treatment of the paranasal sinuses should be evaluated. In summary, upper airway involvement requires prospective investigation and an interdisciplinary consensus on diagnosis and therapy. Background Recent microbiome studies suggest that the airways of individuals with cystic fibrosis (CF) are colonized by a complex microbiota, including strict anaerobes that traditionally inhabit the oral cavity. Prevotella species are consistently one of the most prevalent members of the CF microbiome, however few studies with cultural methods have investigated the antibiotic resistance of these specie in CF. Exposure to antibiotics used routinely in the treatment of CF pulmonary infection may also increase the resistance to antimicrobials even in anaerobic strains. Therefore in this study, we determined the abundance and antimicrobial susceptibility of Prevotella isolates in a cohort of CF patients at Giannina Gaslini Institute.
Materials and methods
Anaerobic and aerobic culture techniques were used to culture sputum samples from 60 (43 adult and 17 pediatric) CF patients. Sputum (20μl) were plated onto Brucella Blood Agar with Hemin and Vitamin K1 (BD) and Schaedler Kanamycin-Vancomycin Agar with 5% Sheep Blood (BD). The plates were incubated under anaerobic conditions at 37°C for 5-7 days then were examined and unique isolates were enumerated and subcultured. The specie identification were performed in duplicate by matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) using a Vitek MS Spectrometer (bioMérieux). To assess the susceptibility of the obligate anaerobe isolates to antibiotics, was used the Thermo Scientific™Sensititre™ Anaerobe MIC Plate. Interpretative criteria for susceptibility to antibiotics were in accordance with Eucast.
Results
We found 70 strains of Prevotella: 39 P. Melaninogenica (56%), 10 P. Denticola (14%), 7 P. Nigrescens (10%), 7 P. Salivae (10%), 3 P. Intermedia (4,3%), 2 P. Oralis (2,9%), 1 P. Baronie (1,4%) and 1 P. Disiens (1,4%). The strains analysed show resistance to Penicillin (MIC90 >8 mg/L), amoxicillin (MIC90 > 32 mg/L), clindamycin (MIC90 > 64 mg/L) and piperacillin (MIC90 = 64 mg/L). All strains were susceptible to metronidazole (MIC90 = 4 mg/L), imipenem (MIC90 = 0.12 mg/L) and piperacillin/tazobactam (MIC90 ≤ 16 mg/L). Conclusions Our study confirms an abundance of Prevotella in lower airway of CF patients. Regarding the antimicrobial susceptibility, previous studies on isolates from CF patients described a high resistance to amoxicillin and macrolides. Our results demonstrate that metronidazole, meropenem/imipenem and piperacillin/tazobactam are likely to be most effective against Prevotella. Further research into anaerobic pathogens, in particular Prevotella, will lead to improve treatments to reduce the severity of CF lung disease.
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The challenge of macroscopic sputum quality assessments with a colour grading system in Cystic Fibrosis Background Lung disease in CF is characterized by airway inflammation, persistent cough with production and stagnation of thick mucus. Sputum samples are a standard part of the clinical assessment of CF patients and are routinely collected for microbial surveillance and respiratory physiotherapy evaluation. Macroscopic sputum assessment, which consists primarily on visual examination of volume, colour, apparent viscosity and patientperceived thickness, is a subjective measurement with a potentially high variability. The aim of the study is to explore the feasibility and agreement of a 5-point colour scale for macroscopic evaluation of sputum colour.
Materials and methods
Clinically stable subjects with CF were recruited during their scheduled follow-up or the day before discharge from hospitalization. After performing a medical examination and spirometry patients were asked to withhold their usual bronchodilator therapy and start their usual airway clearance technique during which a sputum sample was collected by a respiratory physiotherapist (RPT) in a wide mouthed capped plastic container. The sample was assessed with a 5-point colour scale (from 0=lighter to 5=darker) by the patient, two RPTs and two residency doctors (RDs), which were blind to the patient identity, within ten minutes. Samples containing more than minimal salivary contamination were not evaluated. Sign test was used to test for consistent differences between patients and health professionals and within RPTs and RDs. Statistical significance was accepted at p<0.05. Sample characteristics are presented as mean (Table 7) unless specified. Results Nineteen subjects were recruited and a single sputum was collected per each. Six patients were excluded for excessive salivary contamination of the sample. Sputa from 13 subjects (7 females) aged 29(11) years with a FEV 1 of 48,2(20,1%) pred. were assessed. Median colour point was the same within patients, RPTs and RDs (score=4). Sign test revealed agreement in colour assessment between patients and RPTs, patients and RDs, RPTs and RDs. Patients self-assessment scores were lower than the median of RPTs and RDs in 5(38%) subjects. Conclusions Although sputum properties and their changes are not correlated with frequency of infection, use of antibiotics, and quality of life, a sputum colour scale could be an objective useful tool to standardize the macroscopic description of sputum on medical record and progress notes among different health professionals. The study is still ongoing to evaluate agreement on a larger sample size along with a feasibility comparison with a 9-point colour scale. 
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Molecular identification of persistent
Background
In the last few years, the range of lung infections due to emerging and atypical microorganisms has been widen by the increased availability of molecular diagnostic procedures. Pulmonary nocardiosis is a well-recognized cause of disease in patients with risk factors such as immunosuppression, malignancies, and severe lung disease. However, only sporadically, Nocardia spp have been considered pathogenic in CF. In this report we describe the identification by whole genome sequencing (WGS), of N. otitidiscaviarum as the cause of chronic pulmonary disease in BV, a 14 years-old CF girl.
Materials and methods
From October 2014, BV was admitted several times to the CF Centre in Brescia, for pulmonary exacerbations and, in May 2015, TC scan revealed the presence of pulmonary consolidations. To perform routine culture microbiological analyses, sputum and/or bronchoalveolar lavage (BAL) were sampled at each hospital admission. Samples were also subjected to direct gram staining and, in some cases were used for molecular procedures. Briefly, bacterial DNA was extracted using Qiagen kit and sequencing libraries were prepared with the Nextera XT sample preparation kit (Illumina, Inc., San Diego -California, USA). Sequencing was performed on the MiSeq and assembled with MIRA 4.0 using "accurate" settings for de-novo assembly mode.
Results
Despite the clinical condition, BV did not show infection by any canonical CF pathogens, whereas direct microscopy highlighted the presence of gram-positive filamentous bacteria compatible with Actinomycetales. Specific culture conditions (5 days on CAN agar in 5%CO 2 ), applied on all the samples collected from May 2015 to October 2016, allowed to isolate bacteria and to perform antibiograms but not to identify the pathogen. WGS identified the isolates as belonging to the Nocardia otitidiscaviarum species and revealed that they were all clonal.
Conclusions
With no other pathogens detected, the repeated isolation of the same Nocardia otitidiscaviarum clone strongly suggest this bacterium as the sole responsible for the patient's exacerbations. These data confirm that WGS is a useful tool for laboratory analysis during investigations on atypical CF infections sustained by fastidious organisms.
It is important to underline that, in BV, specific treatment for Nocardia is efficient in obtaining symptoms remission; however, analogously to what occur in chronic P. aeruginosa infection, treatment does not eradicate the colonization. This suggests that both clinical and microbiological monitoring using WGS may be helpful to gain a deeper knowledge about the role of Nocardia infection in CF lung pathogenesis. Consent for publication: The patients gave the consent to publish clinical data. Background Non-tuberculous mycobacteria (NTM) are ubiquitarious microorganisms with a borderline pathogenicity; NTM infection are often associated with an increased risk of morbidities in respiratory or systemic diseases and recent data suggests a potential increased frequency of NTM-positive cultures in adult patients with Cystic Fibrosis (CF). The aim of this study is to assess prevalence of NTM-positive culture and the incidence of NTM infections among our CF Centre casuistry.
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Materials and methods
An observational retrospective analysis was carried out from 2010 to 2016 among adult CF patients. Respiratory function indexes (FEV 1 %pred, FVC, FEV 1 /FVC) and nutritional status (BMI) were collected within three months from first NTM isolation and un to one year from the start of treatment. The prevalences of the slowgrowing Mycobacterium avium complex (MAC) and the rapidgrowing Mycobacterium abscessus complex (MABSC) species were calculated. Simple isolations and non-tuberculous mycobacteria pulmonary disease (NTM-PD) were differentiated according to ATS/IDSA 2007 Statement. The efficacy of antimycobacterial therapy was assessed through radiographic imaging, changes in pulmonary function and sputum conversions at 3, 6 and 12 months from isolation (NTM) or from the onset of therapy (NTM-PD). Results One hundred fifty five CF adults were screened for NTM between 2010 to 2016. Among them, 23 patients (10 males), aged 30.5 (18-56) years with a FEV1 % pred. of 70.2 were found to have at least one positive sputum culture for NTM (prevalence of 15%); 41% of NTM positivity is due to MABSC and 38% to MAC. The overall prevalence for NTM-PD was 5% (8 patients) which were treated for NTM-PD with anti-mycobacterial multidrug treatment. There is a statistically significant difference on lung function and BMI between patients with NTM and NTM-PD. Improvements in lung function and nutritional status after treatment haven't reached the statistical significance within the NTM-PD group. The average duration of therapy was 407 (68-609) days with an adverse effects incidence of 55%. Two patients interrupted treatment for serious side effects. In NTM-PD group 78% of patients underwent chronic therapy with azithromycin versus 35% of patients with NTM infection and 38% of NTM-PD patients had more than two pulmonary exacerbations the year before NTM isolation against 29%. Conclusions Prevalence of NTM-positive cultures in our sample is consistent with the literature. The radiological progression of the disease in NTM-PD despite anti-mycobacterial treatment and the considerable drug toxicity in CF adult patients highlights the need for a close monitoring of this population. Background Methicillin-resistant Staphylococcus aureus (MRSA) represents one of the most important new microrganisms that interest patients with cystic fibrosis (CF); it also represents an increasing clinical problem with limited, not always effective, therapeutic options. Because chronic infection with MRSA can be associated with accelerated decline in lung function, its eradication is attempted in most CF centers today. We present two case reports in which chronic infection with MRSA shows two different evolutions. Case reports DM, male 38 years old, with a complete form of CF, chronic infection with MRSA and Pseudomonas Aeruginosa, CFRD, chronic kidney failure, severe osteoporosis, showed since the first MRSA colonization a decline in lung function, with frequent need of hospitalizations, he also developed multi-drug resistance and many adverse reactions to drug. The patient also showed a decline in life quality through the compilation of CFQ-R questionnaire. The patient had always showed a successful adherence to antibiotics therapy and an intensive chest physiotherapy, with great limitations because of multiple adverse reactions to antibiotics with severe symptoms, so it was not always simple to treat lungs exacerbations and we treated him with antibiotics tested in sputum antibiogram. In the last year he was successfully admitted to the hospital for a lung transplant. FC,16 years old, with a complete form of CF, chronic infection with MRSA and also Pseudomonas Aeruginosa, showed since the first colonization from MRSA a decline in lung function, many drug resistance including also resistance to Linezolid, presents many lungs exacerbations, with a great need to hospitalization (10 hospitalization in the last 12 months ). It was not always simple to treat lung exacerbations and we treated him with antibiotics tested in sputum antibiogram. The second patient had not always an optimal adherence to all therapies concerning CF, first of all chest physiotherapy and use of inhaled antibiotics. The patient showed a deep decline of life quality through the compilation of CFQ-R questionnaire because of recurrent hospitalization and lungs exacerbations. Both the patients showed the same clinical and bacteriological situation instead of the presence in the first patient of multiple comorbidity such as CFRD, chronic kideys failure and osteoporosis. Conclusion We want to underline the importance of a correct adherence and compliance to all the therapies concerning CF. This behaviour lead to an improvement of clinical conditions, but also to an improvement of quality of life. Consent for publication: The patients gave the consent to publish clinical data. In this study, we performed a time-resolved analysis of functional and taxonomic feature of lung microbiota in order to identify the key microbiome signatures associated with the increased risk of adverse outcomes and understand how microorganisms evolve in response to changes in clinical conditions along time.
Twenty-one subjects with CF were enrolled in this study and followed over a 15-month period. Sputum samples were taken every three months during clinic visits. Patients were monitored during and after exacerbation. Library construction and metagenomic sequencing were performed following standard pipelines in Illumina Hiseq 2000 platform.
Results
An extraordinary resilience of the main CF pathogens to antibiotic treatment was detected. Hierarchical clustering based on microbial strain-level profiling of marker genes detected from metagenomics samples produced one cluster for each patient, containing all time points including those sampled through one or more exacerbation events. This effect was more evident for the main CF pathogens detected such as Pseudomonas aeruginosa and Staphylococcus aureus, but also for species than can be considered as emerging CF pathogens, such as Rothia mucillaginosa and Prevotella melaninogenica. Taxonomy distribution inferred from metagenomics data was quite heterogeneous both across patients and within time points of the same patient with some species that were not detectable especially during recovery, probably due to the antimicrobial treatment that might have drastically reduced the abundance of pathogen species below the revelation threshold.
Conclusions
Our results revealed that the airway colonization is highly selective and that a single strain, which started it, continues to survive and thrive in the lung of the patient. The possibility to analyze the microbiome dynamics in CF airways will permit to discover novel biomarkers involved in the pulmonary disease dynamics and can give us a set of tools to unlock the potential of microbiome-based personalized medicine in major disease areas including CF.
Background
The Italian Cystic Fibrosis Registry (ICFR) is based on a new agreement (October 2016) signed by Istituto Superiore di Sanità (National Center for Rare Diseases), clinicians of the Italian National Referral and Support Centers for Cystic Fibrosis, Bambino Gesù Children's Hospital, Italian Cystic Fibrosis Society and Lega Italiana for Cystic Fibrosis.
Materials and methods
Analyses and results are referred to patients in charge to the Italian National Referral and Support Centers for Cystic Fibrosis in 2011-14 periods. Data were sent by Centers by means of specific software (Camilla, Ibis Informatica). Data underwent to a double quality control (QC): the first by Istituto Superiore di Sanità (ISS) and the second at a European level (European Cystic Fibrosis Registry). These QCs assure the completeness and accuracy of data as well as their consistency with European core data. Results A total of 29 different CF Centers sent their data to ICFR. Data regarding Sardinia are missing and those from Molise CF Center are exclusively referred to 2014. Estimated CF prevalence was 8,2/100,000 residents in Italy. On average, over the period 2011-2014, 52,1% of patients were male and 53,7% were aged more than 18 years. The majority of patients aged 7 to 35 years. Most of the CF patients were diagnosed before two years of age (around 66%); a significant percentage of patients (12%) was diagnosed in adult-age. In almost all patients, 2 (or more) CFTR mutations were identified. F508del mutation was the most frequent (44,8% in 2014). 135 patients received double lung transplantation (range 7-53 years; median age at transplantation was Background Cystic Fibrosis (CF) is a potential source of distress and there is growing recognition that the child's care must focus on medical therapies and on the psychosocial well-being of patients and their families. We will describe a case report of two siblings that highlights the importance of integrate psychosocial care and standard medical practice. The case underlines the importance of a multidisciplinary approach to achieving global patient well-being.
Materials and Methods
Marco and Francesca come to our medical attention in 2014 for a "second opinion" after being taken care of at another service. They showed pancreatic insufficiency, Pseudomonas Aeruginosa colonization and frequent pulmonary exacerbations. Marco presented: FEV 1 = 70%; food allergy (milk, egg, gluten and nuts) and a severe malnutrition (weight 26 Kg, height 133 cm, BMI = 14.7) that required the placement of a Percutaneous Endoscopy Gastrostomy (PEG). Francesca presented: FEV 1 = 66%; (weight 36 Kg, height 143 cm, BMI = 17.6). They showed psychosocial problems (anxiety and depression symptoms, parental conflict after separation, poor knowledge of disease and poor adherence to treatment). The two brothers were followed up through a multidisciplinary approach that envisaged: a) medical care (hospitalization and day hospital); b) educational sessions about the use and maintenance of the devices, the management of therapy and proper nutrition; c) individual and family psychological support; d) multidisciplinary and systematic meetings of the medical team (doctors, nurses, psychologists, physiotherapists, social workers and dieticians) in order to identify common strategies.
Results
To date we have found: an improvement in Marco's nutritional state (weight 44.00 Kg, height 156 cm, BMI = 18.08%) moreover, the FEV1 values over these three years have reached 84%, thanks to the commitment of the boy in adhering to the care offered by the care team. Francesca also showed an improvement in lung occlusion with a FEV1 89%, increasing compared to its entry into the center; the nutritional state has improved (weight 49.2 Kg, height 155 cm, BMI = 20.4%). In both it has been detected an improvement compared to: nutritional status, better control of pulmonary infections, psychological functioning, awareness of the disease, adherence to therapeutic treatment emotional and social adaptation and coping skills, improving global health and quality of life. Both have joined the center's telemedicine project by regularly broadcasting their values of saturation and spirometry. Conclusions A multidisciplinary approach in a complex chronic condition, such as CF, appears to be a necessary condition for achieving goals that promote the overall well-being of the patient. Consent for publication I declare that I have obtained the consent to publish the clinical data of the two patients. I declare that I have used fantasy names. 
We have conducted the survey in a sample composed by 29 males and 31 females, mean age 26,5 (±10,55); mean BMI 20,76 (±2,67); also 37,7% (n=23) featured exacerbations in the last year and 53,3% (n=32) takes from 5 to 15 drugs. We have measured the level of Patient Engagement in this sample and 20% (n=12) is in the Arousal phase: they are starting to act; 60% (n=36) in the Adhesion phase: they have learned behavioural skills to act in a proactive manner towards the disease. The last 20% (n=12) is in the Eudaimonic project phase: they have fully accepted the disease and they are good stakeholder for a positive engagement. We have measured also the Patient Activation and 50% of the sample (n=30) results to be in a phase of full activation: the patients have realised most of the needed behavioural changes. The last interesting outcome observed is a low adherence to pharmacological therapies in 55% (n=33) of the sample. Furthermore we have analysed the correlations between Patient Engagement and the aforementioned variables (Table 8) .
Conclusions
The study highlights the correlations among Patient Engagement and some important variables: Patient Activation, Self Efficacy and Negative Affect States. These factors are essential to promote a positive engagement. In closing, we have to notice that the low adherence to therapies suggests to improve an effective communication between patient and clinician. ) adult patients (64 males, mean age 34.8 ± 9.7 years) followed at our Centre were screened by the PHQ-9 (Patient Health Questionnaire-9) and GAD-7 (Generalized Anxiety Disorders -7 item) to investigate depression and anxiety scores, respectively. The CFQ-R questionnaire was also submitted. Patients agreed to personal data treatment.
Results
The PHQ-9 score was in the normal range (0-4) in 62 patients (54.9%), between 5 and 9 (mild depression) in 33 patients (29.2%), and > 10, suggesting a moderate-severe depression in 18 patients (15.9%). Considering the GAD-7 questionnaire, we found a normal score in 63 patients (55.8%), a score suggesting a mild anxiety in 33 patients (29.2%) and a score suggesting a moderate-severe anxiety in 17 patients (15.0%). We found a negative correlation between anxiety score and all domains of CFQ-R, except for physical and respiratory domains and between depression score and all domains of CFQ-R, except for respiratory domain.
Conclusions
According to the CFF and ECFS consensus statements about a third of our population should receive a supportive intervention and psychoeducation, and about 15% of our adults should have a psychological and/or psychopharmacological intervention. When we used the HADS scale in a different group of CF subjects, we found a similar prevalence of elevated, > 10, anxiety (17.2 vs 15.4%) but a lower prevalence of elevated, >10, depression (6.6 vs 15.9%) in comparison with the data obtained in this study. We wonder if the proposed modality of screening and treatment for anxiety and depression is also applicable in Italy. Two aspects are critical: i) there is a very small number of psychologists, who works full-time in the Italian CF Centers; ii) the psychological intervention is more directed to improve the coping of patient-family with the disease during specific life times (diagnosis, growth and nutrition, adolescence, self-care and independence, worsening of disease and decisions on organ transplantation, end of life issues).
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Cystic fibrosis is a known disease? 
Background
We present an observational study made to know how cystic fibrosis (CF) is known by two samples: nurses population and society. Materials and Methods Every sample was investigated using a questionnaire. It consists of 18 multiple choise questions, submitted to two samples: the "Nurses" sample, consisting of 50 nurses belonging to different wards not concerning CF and the "Society" sample, including 50 subjects who don't study or work in the healthcare field. Questions was aimed to investigate the CF knowledges about incidence, symptoms, diagnosis, treatment and life expectancy and to understand if the samples know the existence of the CF Center and which healthcare professionals are involved in the patients care.
Results
The results suggest that: 18% of nurses surveyed and 68% of subjects belonging to the "Society" sample don't know CF; 72% of nurses interviewed and 90% of subjects belonging to the "Society" sample don't know people with CF; 2% of nurses and 48% of the "Society" sample say that CF is not a genetic disorder; 70% of subjects in both samples think that CF is a very rare disease; 28% of subjects belonging to the "Society" claim that patients with CF are contagious; 22% of surveyed nurses and 35% of the "Society" sample don't know the organs involved, symptoms, diagnosis and treatments; very often CF is being exchanged for a neurodegenerative/neuromuscular disease; 64% of the two sample don't recognize that life expectancy is greatly improved by the advancement of scientific research, the implementation of new treatments, and the improvement of care processes. Almost 58% of the "Society" sample dont' recognize the existence of the CF Center, which is dedicated to the care and assistance .14% of nurses interviewed and 22% of subjects belonging to the "society" sample doesn't know that there is a CF Center also in Palermo; 14% of nurses surveyed and 36% of subjects belonging to the "Society" sample are not interested in learning more about CF.
Conclusions
The results obtained show that this disease it's not so well-known among two sample due to poor media involvement and also probably due to poor university and post-based training on. These results must make us reflect on the role that healthcare professionals have in educating society about the knowledge of this pathology. It's necessary to increase the awareness of the scientific world and not to give the right attention to CF. Background Rigorous systematic reviews have found that in developed countries, adherence to long-term therapies among patients with chronic disease is only 50% [1] . Cystic fibrosis (CF) is a genetic disease that affects several organs, including the respiratory, digestive and reproductive systems, but above all is a "time-consuming" disease. CF requires complex medical management throughout the patient's life. The therapeutic load becomes increasingly intense with the course of the years and with the worsening of the disease and it is known that adherence to therapies dramatically decreases since adolescence, if not before. Adherence between children and adults with CF varies from 38% for chest physiotherapy to 50% for inhalation therapies and dietary supplements [2] and 68% for the new drug Kalydeco© [3] . Talking about adherence to therapy during an outpatient visit is not always easy and it is not always done. Riekert et al provided a questionnaire to US CF Foundation accredited CF centers, showing that only 8% of respondents measure adherence, and only 64% discuss about adherence during the outpatient followup [4] . The most common used strategy to increase adherence of CF patients is disease education.
Materials and methods
We analyzed the disease awareness of 79 patients older than 8 years followed at the Regional Support Center for CF in Brescia. For each age group (8-11, 12-17,>18) an electronic questionnaire (Google Forms©) was created. Questionnaires were subdivided into thematic sections, each provided with several multiple choice or short answer questions. The topics covered are as follow: knowledge of the disease and self-management, knowledge about health, infection control, chest physiotherapy, lifestyle, psychosocial well-being, sexual education, professional/educational plan and social care. Results Results are reported in Table 9 . Conclusions Below are the key points of educational intervention based on the outcome of our patients' needs:
-Patient education starts at the time of diagnosis and must be integrated into each stage of the evolution of the disease. -All members of the multidisciplinary team must contribute to patient education. -Instructing the patient to self-management of the disease, adapting the information and therapy according to his/her needs. -Developing therapeutic plans in collaboration with all members of the team and patients. -Encourage adherence to the therapeutic regimen.
-Monitor adherence.
Background
Drug reaction with eosinophilia and systemic symptom (DRESS) syndrome is a rare life-threatening hypersensitivity reaction with an estimated incidence between 1:1000 and 1:10000 drug exposures occurring 2-6 weeks after a causative therapy. DRESS syndrome is characterized by skin eruption, fever, elevated liver enzymes and leukocytosis with eosinophilia. Renal, pulmonary, cardiologic and neurologic manifestations may be also associated. This condition may be fatal if unrecognised, especially in patients with hepatic failure. Diagnosis may be difficult, particularly in paediatric and cystic fibrosis (CF) patients in which this condition is rarely described. Case report A 4-year-old girl with CF admitted to our hospital for a pulmonary exacerbation was treated with piperacillin-tazobactam (150 mg/kg/die) and tobramycin (10 mg/kg). After 14 days she developed fever (up to 40°C) and a diffuse maculopapular erythematous rash. Generalized polyadenomegaly and hepatomegaly were also detected. Laboratory investigations revealed a marked increase in C-reactive protein, lactate dehydrogenase, aspartate and alanine aminotransferse and a significant alteration in coagulation tests. On the 18 th of hospitalization hypereosinophilia was also observed (Table 10) . Autoimmune, infective and hematologic detection tests were negative. Due to the clinical features the diagnosis of DRESS syndrome was performed and the ongoing antibiotic treatment discontinued. Without others therapies, clinical resolution was progressively achieved. Conclusions CF patients have an increased incidence of adverse drug reactions due to the heavy therapeutic burden they are exposed in order to prevent progressive lung damage. To our knowledge, this is the first report of DRESS in a paediatric patient with CF. Due to its highly variable clinical presentation, DRESS may be difficult to diagnose as it can mimic infections, autoimmune diseases, hematologic and lymphocytic disorders. Our case highlights the importance to be aware of this condition as the removal of the offending drug is the main management step for the resolution of the clinical and laboratory features. Consent for publication: The authors confirm written informed consent was obtained from the patient's parents.
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The support of the thoracic ultrasound in the reexpansion techniques of a lung parenchymal atelectasic area: case report Matteo Giuliari Background Atelectasia is a non ventilated lung parenchyma area which is a possible complication of many lung diseases, including Cystic Fibrosis (CF). The treatment of this pathological event includes the use of reexpansion techniques through positive pressure devices, such as continuous positive airway pressure (CPAP) and facilitating postures. Atelectasia is detectable through diagnostic imaging examinations such as radiographic examination (RX), computed tomography (CT) and magnetic resonance imaging (MRI), which provide a static image of the involved parenchymal damage. An additional tool in the diagnostic imaging examinations is thoracic ultrasound (TUS), which in addition to the static image, is able to return a dynamic evaluation of the functional response of non-ventilated areas during breathing. This allows to evaluate in real time the ability of parenchyma to reexpand during the application of physiotherapy techniques.We describe a clinical case of pulmonary atelectasis in the lingular site, detected at MRI and treated with non invasive ventilation (NIV) for drainage and CPAP for reexpansion in posture during TUS monitoring.
Case report
Twenty four-year-old female patient with CF, admitted to Trentino Provincial CF Support Center for intravenous antibiotic therapy. On 10th day, MRI showed alteration of lung echoes with longitudinal and transverse extension of about 3 cm, compatible with atelectasic area at the lingular site. TUS was used at T0 to identify the atelectasia in order to set the application of physiotherapy techniques and at T1 (24 hours), as outcome measure. Physiotherapy program for bronchial drainage consisted of NIV (IPAP 13 cmH2O, EPAP 5 cmH2O), 3 times in 24 hours, followed by CPAP application for reexpansion, set at 8 cmH2O in semi-supine and right side facilitating posture, for 1 hour.
The patient allowed the personal data treatment. After the application of 3 physiotherapy sessions of bronchial drainage, followed by CPAP techniques, the small area compatible with atelectasia was almost no longer recognizable at TUS monitoring. Conclusion TUS is a complement to current imaging techniques that can help the respiratory physiotherapist to set, quantify and modify its treatment in real time. The exam is quick, non-invasive, with no side effects and can be performed even for bedridden patients. It requires trained medical personnel and a multidisciplinary team work. Consent for publication: The patients gave the consent to publish clinical data. Background Cystic fibrosis (CF) is the most common recessive genetic disorder in Caucasian population. The suspicion of disease comes from the detection of typical symptoms, family history and newborn screening (NBS). NBS is the only tool that allows reaching an early diagnosis lowering disease severity, burden of care and costs. The first step is based on the dosage of Immunoreactive trypsin (IRT) on spot of blood taken between 3rd-5th day of life. Intermediate tiers are required to achieve an acceptable combination of sensitivity and specificity: second IRT test, CFTR mutation analysis. Sweat test is the gold standard used to confirm the diagnosis.
Materials and methods
The NBS protocol used in Palermo is IRT-IRT-DNA. If the first IRT is > 54 ng/ml a second test is made with the same sample to increase test accuracy. If is still > 58 ng/ml a second sample is collect at about 3-4 weeks and if results still high infants are involved for the genetic test. Detection of CFTR gene mutations defines the diagnosis and help to predict the phenotype. Positive NBS are followed by confirmatory sweat-test. Results Over a 12 months period (01/09/16-30/09/17) in Palermo we had 17 new cases of CF. Six cases were not screened because born before the introduction of NBS. Genetic test was performed in adulthood (two patient's parents and four people with infertility). One case results unknown (performed abroad). Eleven cases were screened with four positive test. In six cases, the screening programme failed. One of our false negative case had meconium ileus. Another one had low haematocrit value that altered the result. The others were not detected due the high cut off value adopted. All these cases were suspected for symptoms potentially related to CF (hypocloremic metabolic alkalosis, dehydration, acute pancreatitis, meconium ileus, poor growth) but a sweat test and DNA study were delayed because of false reassurance from the fact that the child were screened. Conclusions False negativity can be associated with laboratory errors, bad choice of cut-off values, pancreatic sufficiency, meconium ileus. The choice of the centile-cut-off affects the screening's efficacy and is a compromise between the need for good accuracy and economic and social costs. Considering the high prevalence of false negativity, our centre is working to increase test sensitivity lowering the first IRT cut-off, to make a second test on the same sample (from 54 to 50 ng/ml) and defining the second IRT cutoff 40 ng/ml at 3-4 weeks of age. 
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Background
To report the clinical course of a preterm infant with diagnosis of cystic fibrosis. Case report A female infant was born via cesarean section for podalic presentation secondary to premature onset of labor, weighing 1140 g at 28 weeks and 3 days of gestational age, with Apgar scores of 3 and 7. Her mother had attended many prenatal consultations with negative serology for vertical infections and normal obstetrical ultrasound. Immediately after birth, the infant was referred to the neonatal critical care unit due to early respiratory distress, abdominal distension and frequent regurgitations. Serial abdominal radiographs revealed air fluid levels. Initially she was stabilized with nasogastric and rectal decompression. In the tenth day of life the patient underwent laparotomy surgery for intestinal occlusion/ meconium ileus. Ileal resection and two ileostomies were performed, followed by reconstruction of the bowel transit at 17 days of life. She had late neonatal sepsis during the hospital stay, requiring prolonged antibiotic therapy. She was intermittently ventilator dependent, secondary to multiple surgical procedures and sepsis. Two transfusions of red blood cells were performed. Parenteral nutrition was gradually transitioned to infant formula and pancreatic enzyme supplements with satisfactory weight gain. On the basis of her complicated clinical course, Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) mutation analysis had been performed using the Cystic Fibrosis Genotyping Assay (Celera-Abbott). Mutation analysis showed homozigosity for the common CFTR mutation [delta]F508. The sweat chloride test was carried out with a positive result (89 mEq/L). At three months her chest X-ray revealed left pulmonary hyperinflation and right pulmonary consolidation compatible with pneumonic disease. After culture, and based on the microorganism isolated from the upper respiratory tract secretion (Klebsiella pneumoniae and Escherichia coli), antibiotic therapy was prescribed. After prolonged hospitalization, she was discharged home, but after few days she was hospitalized again for bronchiolitis. Laboratory tests for respiratory syncytial virus was positive. During hospitalization, due to progressive worsening of the respiratory pattern, noninvasive ventilation (HFNC) was applied for seven days. She was discharged home on room air and she has not been hospitalized anymore. Ongoing she receives continuous care from paediatric cystic fibrosis centre, has a good nutritional status taking infant formula with pancreatic enzymes supplementation and performs PEP-mask physiotherapy with benefit. Conclusion This case report highlights the importance of advanced neonatal care with cystic fibrosis therapy, and in particular the joint management of two care units and of appropriate treatment of bronchiolitis in CF patient. Consent for publication: Patient's parents signed consent for the publication of patient's clinical data.
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Efficacy and safety of Kalydeco oral granules: the experience of our centre Fabiola De Gregorio, Antonella Tosco, Alida Casale, Angela Sepe, Chiara Cimbalo, Andrea Catzola, Alice Castaldo, Laura Salvadori, Valeria Raia Cystic Fibrosis Center, Department of Translational Medical Sciences University of Naples "Federico II", Naples, Italy Correspondence: Fabiola De Gregorio (fabioladegregorio@yahoo.it) Italian Journal of Pediatrics 2018, 44(Suppl 1):P29 Background Ivacaftor (Kalydeco, Vertex Pharmaceuticals) is the first CFTR potentiator approved for the treatment of cystic fibrosis (CF) patients carrying at least one gating mutation. On January 2016 AIFA approved KALY-DECO oral granules for patients aged 2-5 years/weight <25Kg. We report our experience with patients in treatment with Kalydeco oral granules.
Materials and methods
We evaluated patients treated with Kalydeco oral granules since 2016. Patients underwent visit every 4 weeks for the first 3 months, then every 3 months. Sweat test was performed within 14 days of therapy. The following data were registered each visit: sweat Cl, weight, height, BMI, vital signs, physical examination, renal, hepatic and pancreatic profile, spirometry and six-minutes walking test (6MWT) (if available), sputum/pharyngeal aspirate colture. Ophthalmological and TC examination (sinus and lung) was performed at baseline and after 6 months and 1 year of treatment, respectively. CFQR was administered at baseline, after 8 weeks and 24 weeks of therapy, then every 24 weeks. Each adverse event was noted. Results Four patients, mean age 5.6 years (range 3.6-8.3), 3 F, started therapy with Kalydeco oral granules. CFTR gene analysis showed the following mutations: 2/4 G1244E, 1/4 S549N, 1/4 G178R. 2/4 had pancreatic sufficiency. 2/4 had history of recurrent acute pancreatitis with high amylase (AMS) and lipase (LPS) values at baseline in 1/2. Mean age at baseline was 4.9 years (range 3.1-7.9). Mean follow-up was 34 weeks (range 9-62). Mean Cl value at baseline was 78.5 mEq/l (range 67-86). Through the treatment Cl values decreased <60mEq/l since day 14. Weight increases in 3/4 patients. No pulmonary exacerbations were observed, except in 1 patient. Only in 1 patient change in FEV1, 6MWT and CFQR was evaluated with an increase in FEV1 of 9.67% and in CFQR respiratory score of 8.3 at week 8. Only 1 patient performed TC exam: no bronchiectasis and no change from baseline were reported. None of patient registered change in serum chemical and hematologic tests, in faecal elastasis and sputum culture. Normalization of AMS e LPS was observed in the patient with pancreatitis. Headache, upper respiratory tract infection, nasal congestion occurred in 2/4. No ocular anomalies were detected. Conclusions Ivacaftor has been confirmed as an effective and safe drug, even in our small cohort of young patients. Further long term observation is needed to evaluate a significant clinical improvement of other important disease features as glucose and bone metabolism. Consent for publication: Written informed consent was obtained from the patient's parents. 
Background
Ivacaftor is a CFTR potentiator that corrects chloride transport in most CFTR class III mutations affecting channel gating, some class IV mutations exhibiting abnormal gating or conductance defect and several missense mutations associated with defects in protein processing or function. Ivacaftor is globally approved for class-III and R117H CFTR mutations and, in the United States, for further 28 mutations (23 missense mutations and 5 splicingaffecting mutations) resulting in partially functioning CFTR protein. The 3272-26A→G variant is a class V mutation. Phenotype associated to this variant is variable, with either mild and severe lung disease described; pancreatic sufficiency (PS) is frequent. The 3849+10kbC→T variant is also a class V mutation. Phenotype of patients having the 3849+10kbC→T variant is highly variable, with lung disease delayed in onset in most of these patients, but then become severe in some. The majority of patients have PS, borderline or normal sweat chloride (SCL) values and sometimes male fertility. We describe the effectiveness and safety of Ivacaftor in two women with CF with the CFTR genotype 3272-26A→G /E585X and 3849+10kbC→T /F508del, respectively, with severe lung disease.
Materials and methods
Ivacaftor 150 mg bid was started after a request of compassionate use was approved by the local Ethics Committee (EC). Before starting the therapy with Ivacaftor, a basal assessment was performed (lung function, 6-minute walking test (6MWT), CFQ-R questionnaire, sweat test, biochemical tests, microbiology test, ophthalmologic evaluation). Data about lung function, 6MWT, antibiotic therapies were retrieved by the local database. Subjects were admitted as outpatients once a month.
Results
Main results are summarized in Table 11 . The administration of Ivacaftor resulted in improvement of lung function, 6MWT, CFQ-R scores and a decrease of antibiotic therapy in both patients. Sweat chloride decreased only in the patient with 3849 +10kbC→T/F508del genotype, whereas nutrition and sputum microbiology were unchanged. No safety concerns were registered for both patients. Conclusions These cases expand our knowledge about potential benefits of Ivacaftor for CFTR mutations with RF, including certain mutations affecting splicing. The clinical and functional improvement in subjects with severe lung damage suggests that Ivacaftor could alter the natural history of the disease, when an adequate target is present, as a CFTR with altered gating function or defective conductance or a quantitative partial defect of CFTR, as in presence of mutations affecting splicing.
Consent for publication:
The patients gave the consent to publish clinical data. Background Cystic fibrosis (CF) is a life-limiting disease that is caused by defective or deficient CF transmembrane conductance regulator (CFTR) protein activity. Phe508del is the most common CFTR mutation with high rates of premature death. It is a multisystem disease that is characterized by pancreatic insufficiency and chronic airway infections associated with loss of lung function, repeated pulmonary exacerbations. Lumacaftor is a CFTR corrector that has been shown in vitro to correct Phe508del CFTR misprocessing and increase the amount of cell surface-localized protein. Ivacaftor is an approved CFTR potentiator that increases the open probability of CFTR channels. The TRAFFIC and TRANSPORT trials were two phase 3, multinational, randomized, double-blind, placebo-controlled, parallel-group studies in which Lumacaftor was orally administered combined with Ivacaftor.
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Materials and methods
Between March 2016 and September 2017 at the Regional Reference Center of Palermo for the CF, a total of 7 patients in critical need (female:5, male:2) aged 17-44 years (mean 26,6) with CF, who were homozygous for the Phe508del, were enrolled and assigned to receive Lumacaftor/Ivacaftor. At first we evaluated auxometry (weight, hight and BMI), respiratory function (%FEV 1 and %FVC), ECG, liver, pancreatic and renal function, sweat test, respiratory infections and CFQR. Patients agreed to personal data treatment. Results Significant improvements in the percentage of predicted FEV1 were seen, the respiratory function got better in term of FEV1 an FVC in this 18 month of observation: FEV1 + 11,4 % after 3 months (T3), + 12,2% after 6 (T 6 ), +9,8 one year later (T 12 ) and + 6,8 at the end of the observation (T 18 ). Also the FVC increased of 10,4 %, 13%, 9,3% and 9,5% respectively after 3, 6, 12 and 18 months (T 3 , T 6 , T 12 , T 18 ). We observed the improvement of the mean-BMI: +0,16 percentage points after six months (T 6 ) and 0,21% at the end (T 18 ) (Table 12) . We recorded nine cases of pulmonary exacerbations and any side effects at the end, except for a patient who suffered of a subopacity of the crystalline. The sweat test results were not reliables. The quality of life was investigated by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) respiratory symptom scale, that revealed an improved tolerance to effort and a decreased night bronchorrea.
Conclusions
The discovery of this therapeutic strategies gave new prospective of life to the patients who carried a Phe508del mutation in CFTR. Our data demonstrated, according to the international literature, that combination therapy of Lumacaftor/Ivacaftor improves the respiratory function and the quality of life of these patients.
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